Radiation Therapy During and After Lumpectomy in Treating Women With Stage I or Stage II Breast Cancer
This trial is active, not recruiting.
|Treatments||adjuvant therapy, therapeutic conventional surgery, intraoperative radiation therapy, radiation therapy|
|Collaborator||National Cancer Institute (NCI)|
|Start date||October 2002|
|End date||June 2005|
|Trial size||80 participants|
|Trial identifier||NCT00647582, 1681-02, CDR0000588774, MCS066, P30CA015083|
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy during and after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This phase II trial is studying the side effects of giving radiation therapy during and after lumpectomy and to see how well it works in treating women with stage I or stage II breast cancer.
Local tumor control rate
Distant tumor control rate
Long-term side effects
Female participants from 18 years up to 99 years old.
DISEASE CHARACTERISTICS: - Histologically confirmed primary invasive breast carcinoma, meeting the following criteria: - Stage I or II disease (T1-T2, N0, M0) - Tumor pathologically determined to be ≤ 5 cm in diameter - Single, discrete, well-defined primary tumor - No multicentric disease and/or diffuse malignant appearing microcalcifications - Any microcalcifications must be focal - Specimen radiograph is required after lumpectomy to assure removal of all malignant appearing calcifications - No axillary lymph node involvement - Axillary lymph node status can be determined by level I and II lymph node dissection or sentinel lymph node sampling - Must have pathologically negative surgical margins - No evidence of metastatic breast cancer - Hormone receptor status not specified PATIENT CHARACTERISTICS: - ECOG performance status 0-2 - Menopausal status not specified - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No pre-existing collagen vascular disease except rheumatoid arthritis that does not require immunosuppressive therapy PRIOR CONCURRENT THERAPY: - No prior irradiation to the area of planned radiation field - Concurrent hormone therapy allowed
|Official title||Phase II Study of Intra-operative Electron Irradiation and External Beam Irradiation After Lumpectomy in Patients With Stage T1N0M0 or T2N0M0 Breast Cancer|
|Description||OBJECTIVES: - To determine the feasibility and acute tolerability of intraoperative electron radiotherapy (IOERT) and external-beam radiotherapy (EBRT) after lumpectomy in women with stage I or II breast cancer treated with breast conservation therapy. - To determine the local tumor control and distant tumor control rates in these patients. - To determine the long-term side effects and cosmetic outcome of IOERT to the tumor bed and EBRT after lumpectomy in these patients. OUTLINE: Patients undergo standard lumpectomy. Patients with negative lymph nodes undergo intraoperative electron radiotherapy to the tumor bed. Beginning 2-8 weeks after surgery, patients undergo whole breast external beam radiotherapy once daily for 24-27 fractions. After completion of study treatment, patients are followed periodically for up to 8 years.|
Call for more information